Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney, Islet Allograft Survival and Function in Nonhuman Primates
Portfolio Pulse from Benzinga Newsdesk
Eledon Pharmaceuticals has announced the publication of data showing that treatment with Tegoprubart promotes kidney and islet allograft survival and function in nonhuman primates.
September 06, 2023 | 11:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eledon Pharmaceuticals' Tegoprubart has shown positive results in nonhuman primate studies, potentially indicating a positive future for the drug.
The positive results from the nonhuman primate studies of Tegoprubart indicate a potential for success in human trials and eventual market success. This could lead to increased investor confidence and a rise in Eledon Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100